What endeavor otc does

EndeavorOTC is a consumer digital therapeutic for adults 18+ with ADHD, developed and operated by Akili Interactive Labs, Inc., a privately held US corporation. The product is delivered as a mobile video game on iOS and Android, available without a prescription and distributed through the iOS App Store, Google Play, and the company website. It targets adults with primarily inattentive or combined-type ADHD who seek to improve attention, focus, productivity, and quality of life — including adults already on stimulant medication and those seeking a non-pharmaceutical alternative to traditional ADHD drugs.

The underlying platform is a patented, FDA-authorized adaptive technology that uses a dual-task paradigm: users simultaneously complete a targeting task (tapping specific stimuli while ignoring distractions) and a navigation task (steering through courses while avoiding obstacles). Difficulty adjusts in real time via an adaptive algorithm that measures performance and modifies speed and challenge to maintain therapeutic intensity. The product also generates a personalized "Focus Score" (0–100), derived from navigation ability, target-collection speed, and target-selection accuracy, with a projected 6-week target of 12–34 points of improvement. The technology is the same patented stack behind EndeavorRx, the FDA-authorized prescription video game treatment for pediatric ADHD (ages 8–12), and EndeavorOTC is made available under the FDA's Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders during the COVID-19 Public Health Emergency. Clinical validation from a 220+ participant trial reported 73% quality-of-life improvement, 83% clinical focus improvement, and improvements nearly 7x larger than the EndeavorRx pediatric trial.

EndeavorOTC operates a direct-to-consumer, product-led growth model with a three-tier subscription: $24.99/month, $99.99 every six months ($16.66/mo), and $129.99 annually ($10.83/mo). Subscriptions can be purchased on the website or via in-app purchase through Apple and Google. Marketing channels are digital-first — app store listings, Facebook, Instagram, blog content, and email — targeting US consumers with a money-back guarantee for users who play 6 weeks at 50+ minutes/week without attention improvement. The product is FSA/HSA eligible and is currently restricted from international use due to device compatibility concerns. There is no disclosed revenue, headcount, or institutional funding data in the source materials.

Name

endeavor otc

Legal name

Akili Interactive Labs, Inc.

Website

https://endeavorotc.com

Company type

Private

Operating status

Operating

Short description

EndeavorOTC, a product of Akili Interactive Labs, provides an FDA-authorized digital therapeutic video game for US adults 18+ with ADHD. Available without prescription via iOS, Android, and direct website, it uses an adaptive dual-task algorithm and Focus Score metric to improve attention on a subscription basis.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Executive Functioning & Behavioral Support Tools (ADHD, SEL/Behavior Tracking, Routines) (EDAFAKAG)

Keywords

• Digital therapeutics
• Adult ADHD treatment
• Cognitive training apps
• Attention therapy
• Mobile health application

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Subscription (Direct to Consumer): Monthly and annual subscription plans for access to EndeavorOTC mobile application. Three tiers: 1-month ($24.99/mo), 6-month ($99.99), and 12-month ($129.99). Subscriptions auto-renew unless cancelled 24 hours before renewal.
2. In-App Purchase (iOS/Android): Subscriptions available through iOS App Store and Google Play in addition to direct website purchase.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

EndeavorOTC is a mobile video game-based digital therapeutic developed for adults aged 18 and older with primarily inattentive or combined-type ADHD. It uses FDA-authorized technology to deliver adaptive dual-task cognitive challenges designed to improve attention and focus. The product is sold directly to consumers over the counter, without requiring a prescription.

Product overview

EndeavorOTC is a single digital therapeutic mobile application for adult ADHD (18+), available without prescription. The portfolio includes two products built on the same core technology platform: EndeavorOTC for adults (non-prescription) and EndeavorRx for children 8-12 (FDA-authorized prescription). Both products use an action video game interface with adaptive difficulty to improve attention and focus through multitasking challenges.

Differentiator

Problem solved

Functional benefit

Brands

• Akili: Digital therapeutics company specializing in treatments for cognitive impairments such as focus and attention
• EndeavorRx
• Akili Assist
• Focus Score

Products and services

• EndeavorOTC Mobile App

Quantifiable outcome

• 73% of participants reported quality of life improvements (measured by validated AAQoL scale)
• +8 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Akili InteractiveflagshipStrategic or Co-development PartnerAkili Interactive is the maker of EndeavorOTC. Both EndeavorOTC and EndeavorRx (FDA-authorized pediatric ADHD treatment) are products developed and offered by Akili. EndeavorOTC is built with the same patented technology as EndeavorRx, the world's first FDA-authorized prescription video game treatment for pediatric ADHD.

Scale indicators6 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Akili Interactive (EndeavorRx): Akili Interactive is the parent company that develops and distributes EndeavorOTC; its EndeavorRx product uses the identical patented technology platform for pediatric ADHD (ages 8-12). It is the most direct comparator as the same dual-task adaptive algorithm, clinical evidence base, and corporate operations underpin both products.
• Cerebral: Cerebral is a direct-to-consumer telehealth platform prescribing controlled substances (including stimulants) for adult ADHD. Comparable as a competing DTC ADHD treatment channel for the same adult patient, though Cerebral focuses on pharmacotherapy rather than digital cognitive training.
• Done: Done is a DTC telehealth subscription service specializing in adult ADHD diagnosis and ongoing stimulant prescription management. It pursues a similar recurring-subscription, app-accessible model targeting the same self-pay adult ADHD consumer that EndeavorOTC serves.
• Big Health: Big Health is a digital therapeutics company commercializing FDA-cleared products (Sleepio for insomnia, Daylight for anxiety) via payer and employer channels. It is a direct peer as a fellow evidence-based prescription-grade digital therapeutic targeting cognitive/behavioral conditions.

Broad incumbents

• Headspace Health: Headspace Health combines the Headspace meditation app with Ginger therapy/coaching for a broad mental wellness platform. It competes for the same DTC consumer attention and employer benefit dollars, but addresses general mental wellbeing rather than the specific cognitive training niche EndeavorOTC occupies.
• BetterHelp: BetterHelp is the largest direct-to-consumer online therapy subscription platform. It addresses the same ADHD consumer need (behavioral support and coping strategies) but through human therapist matching rather than a digital therapeutic, making it a broader incumbent in the OTC mental health subscription category.
• Talkspace: Talkspace is a publicly-traded online therapy and psychiatry subscription platform with significant adult ADHD prescribing volume. Overlaps with EndeavorOTC on DTC subscription distribution and ADHD treatment, though therapy/medication rather than cognitive training is its primary modality.

Emerging players

• Inflow: Inflow is a DTC subscription app combining ADHD psychoeducation, community support, and habit-tracking. It targets the same adult ADHD self-pay consumer seeking non-pharmaceutical support, positioning as a lower-cost alternative to clinical digital therapeutics.
• Woebot Health: Woebot Health develops AI-chatbot-based digital therapeutics for mental health conditions including depression and anxiety. It overlaps as an emerging digital therapeutic company pursuing FDA-grade evidence and consumer/payer distribution for cognitive and behavioral indications.
• Pear Therapeutics: Pear Therapeutics was a pioneering FDA-authorized prescription digital therapeutics company (reSET, reSET-O, Somryst) that filed for bankruptcy in 2023 and has since been restructured. It is a relevant historical peer and cautionary reference for the commercial trajectory of evidence-based digital therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/people/EndeavorOTC/100092517585851
• Instagraminstagram.com/endeavorotc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about endeavor otc